All the news Showing 10 of 111 articles from: Disease course and symptomsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Epigenetic changes persist after hepatitis C cure in liver cells, may predict liver cancer Keith Alcorn / 26 March 2019 Hepatitis C infection leaves permanent changes in the activity of genes in the liver even after the infection is cured and these changes are associated with an increased risk of liver cancer, ... Hepatitis C treatment reduces risk of diabetes Liz Highleyman / 18 March 2019 Treatment of hepatitis C virus (HCV) infection is associated with better glucose control and a lower likelihood of developing diabetes, according to a report at the Conference on Retroviruses and Opportunistic Infections (CROI ... Hepatitis C cure does not improve glucose control in type 2 diabetes Michael Carter / 07 February 2019 A successful response to hepatitis C virus (HCV) therapy does not result in long-term improvements in glucose metabolism for people with type 2 diabetes, according to US research published in Liver International. A sustained ... Immunotherapy combinations show promise for liver cancer Liz Highleyman / 04 February 2019 Checkpoint inhibitor immunotherapy combinations may slow disease progression in people with hepatocellular carcinoma (HCC), according to two small studies presented at the 2019 Gastrointestinal Cancers Symposium last month in San Francisco. However, response ... Aspirin use associated with lower risk of liver cancer Liz Highleyman / 13 November 2018 Taking aspirin about twice a week for five years or more may reduce the risk of developing hepatocellular carcinoma (HCC) by about half, according to research presented this week at the AASLD Liver ... The incidence of diabetes, stroke and kidney disease falls after hepatitis C cure Keith Alcorn / 12 November 2018 The incidence of some of the most serious extrahepatic health problems caused by hepatitis C declines sharply after the infection is cured by antiviral treatment, a review of people treated for hepatitis ... US FDA approves pembrolizumab immunotherapy for liver cancer Liz Highleyman / 12 November 2018 The US Food and Drug Administration last week granted accelerated approval for pembrolizumab (Keytruda), an immunotherapy drug known as a checkpoint inhibitor, for people with hepatocellular carcinoma (HCC). Over years or decades chronic hepatitis B ... What support do people with liver cirrhosis and their families need? Keith Alcorn / 09 October 2018 People with liver cirrhosis and their families need more information about their condition and prognosis and greater access to palliative care, a systematic review of studies on the needs of people with cirrhosis ... Deaths from end-stage liver disease due to HCV fall in United Kingdom Keith Alcorn / 22 August 2018 Deaths from end-stage liver disease and liver cancer caused by hepatitis C in the United Kingdom fell by 11% in 2017, provisional figures from Public Health England released on 28 July show. Most ... Local therapy with sorafenib does not improve liver cancer survival Liz Highleyman / 23 April 2018 Combining sorafenib (Nexavar) with internal radiation therapy or transarterial chemoembolization did not improve overall survival for people with liver cancer, but it did appear to help certain groups of patients, according to research presented ... ← Prev12345...12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Transmission and prevention Diagnosis and monitoring Disease course and symptoms HCV and coinfections Living with HCV Treatment issues Side effects Therapies Liver transplants Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive